Back to results
US 11,598,778 B2Granted
Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsLarisa J. Geskin, Brittany Lynn O'Neill Dulmage, Louis D. Falo, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
Claims11
A method of diagnosing cutaneous T-cell lymphoma (CTCL) in a subject, comprising:
- (a) obtaining a biological sample from a subject;
- (b) contacting the biological sample with means for determining expression levels of TOX, PLS3, KIR3DL2, GATA3, and RUNX3;
- (c) determining levels of expression of TOX, PLS3, KIR3DL2, GATA3, and RUNX3 in the biological sample of the subject relative to expression levels in a biological sample of a subject who does not suffer from CTCL,
- (d) providing a diagnosis of CTCL, wherein the determined expression level of TOX is more than 5 fold;
- the determined expression level of PLS3 is more than 10 fold;
- the determined expression level of KIR3DL2 is more than 5 fold;
- the determined expression level of GATA3 is more than about 1.75 fold;
- and the determined expression level of RUNX3 is less than about 60%;
- all relative to the expression levels of a subject who does not suffer from cutaneous T-cell lymphoma.
6 more elements
Dependencies are inferred from the claim text.